0000000000388546

AUTHOR

Stefan Wölfl

showing 3 related works from this author

Liver-Kidney-on-Chip To Study Toxicity of Drug Metabolites

2017

Advances in organ-on-chip technologies for the application in in vitro drug development provide an attractive alternative approach to replace ethically controversial animal testing and to establish a basis for accelerated drug development. In recent years, various chip-based tissue culture systems have been developed, which are mostly optimized for cultivation of one single cell type or organoid structure and lack the representation of multi organ interactions. Here we present an optimized microfluidic chip design consisting of interconnected compartments, which provides the possibility to mimic the exchange between different organ specific cell types and enables to study interdependent cel…

0301 basic medicineKidneyCell typeBiomedical Engineering02 engineering and technologyComputational biologyBiology021001 nanoscience & nanotechnologyBiomaterials03 medical and health sciencesTissue culture030104 developmental biologymedicine.anatomical_structureDrug developmentToxicityHepatic stellate cellOrganoidmedicine0210 nano-technologyDrug metabolismBiomedical engineeringACS Biomaterials Science & Engineering
researchProduct

Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: Antiproliferative effects, cellular …

2018

Fluorescent 4-ethylthio-1,8-naphthalimides containing rhodium(I) N-heterocyclic carbene (NHC) and ruthenium (II) NHC fragments were synthesised and evaluated for their antiproliferative effects, cellular uptake and DNA-binding activity. Both types of organometallics triggered ligand dependent efficient cytotoxic effects against tumor cells with the rhodium(I) NHC derivatives causing stronger effects than the ruthenium (II) NHC analogues. Antiproliferative effects could also be observed against several pathogenic Gram-positive bacterial strains, whereas the growth of Gram-negative bacteria was not substantially affected. Cellular uptake was confirmed by atomic absorption spectroscopy as well…

Intercalation (chemistry)Fluorescent DyeLigands01 natural sciencesAntineoplastic Agentchemistry.chemical_compoundNeoplasmsDrug DiscoveryMoietyCell DeathBacterial InfectionsGeneral MedicineIntercalating AgentsNaphthalimideAnti-Bacterial AgentsRutheniumNaphthalimidesSettore CHIM/03 - Chimica Generale E InorganicaHumanStereochemistrychemistry.chemical_elementAntineoplastic AgentsLigandCarbene010402 general chemistryG-quadruplexBacterial InfectionRutheniumRhodiumCell Line TumorAnti-Bacterial AgentOrganometallic CompoundsG-QuadruplexeHumansRhodiumBioorganometallicFluorescent DyesGroup 2 organometallic chemistryCell ProliferationPharmacologyOrganometallic CompoundBacteria010405 organic chemistryLigandOrganic ChemistryIntercalating Agent0104 chemical sciencesG-QuadruplexeschemistryNeoplasmDrug Screening Assays AntitumorCarbene
researchProduct

Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance

2020

Background: The extracellular signal-regulated kinase (ERK) pathway regulates cell growth, and is hyper-activated and associated with drug resistance in hepatocellular carcinoma (HCC). Metabolic pathways are profoundly dysregulated in HCC. Whether an altered metabolic state is linked to activated ERK pathway and drug response in HCC is unaddressed. Methods: We deprived HCC cells of glutamine to induce metabolic alterations and performed various assays, including metabolomics (with 13C-glucose isotope tracing), microarray analysis, and cell proliferation assays. Glutamine-deprived cells were also treated with kinase inhibitors (e.g. Sorafenib, Erlotinib, U0126 amongst other MEK inhibitors). …

Life sciences; biology0301 basic medicineSorafenibMAPK/ERK pathwayCarcinoma HepatocellularResearch paperMAP Kinase Signaling SystemGlutamineProliferationlcsh:MedicineAntineoplastic AgentsGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineDownregulation and upregulationddc:570medicineSerineHumansHCCProtein Kinase InhibitorsCell Proliferationlcsh:R5-920Cell growthChemistryKinaseMicroarray analysis techniquesLiver Neoplasmslcsh:RGeneral MedicineHep G2 Cellsdigestive system diseasesMetabolic pathway030104 developmental biologyAnaerobic glycolysisDrug Resistance NeoplasmKinase inhibitors030220 oncology & carcinogenesisCancer researchMetabolomeMetabolic stateAerobic glycolysisTranscriptomelcsh:Medicine (General)medicine.drugEBioMedicine
researchProduct